[造血干细胞移植中脐带血单位选择的更新(SFGM-TC 研讨会)]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-03-13 DOI:10.1016/j.bulcan.2024.01.009
Valérie Dubois, Lucie Blandin, Marion Duclaut, Alix Duquesne, Lionel Faivre, Romain Ferru-Clement, Jean Roy, Alexandre Walencik, Leonardo Magro, Federico Garnier
{"title":"[造血干细胞移植中脐带血单位选择的更新(SFGM-TC 研讨会)]。","authors":"Valérie Dubois, Lucie Blandin, Marion Duclaut, Alix Duquesne, Lionel Faivre, Romain Ferru-Clement, Jean Roy, Alexandre Walencik, Leonardo Magro, Federico Garnier","doi":"10.1016/j.bulcan.2024.01.009","DOIUrl":null,"url":null,"abstract":"<p><p>Changing practices and the limited use of cord blood units as a source of cells for allogeneic hematopoietic stem cell transplants (HSC) led us to reconsider the recommendations established in 2011 and 2012, and to propose an update incorporating recent bibliographic data. If HLA compatibility was until now established at low resolution for HLA-A and B loci, and at high resolution for HLA-DRB1, the recent papers are converging towards an increase in the level of resolution, making way for a compatibility now defined in high resolution for all the considered loci, and the inclusion of the HLA-C locus, in order to establish a level of HLA compatibility on 8 alleles (HLA-A, B, C and DRB1). The CD34+ dose is a determining factor in hematopoietic reconstitution but it is not correlated with the total nucleated cells content. This is why we recommend taking these two data into account when choosing a cord blood unit. The recommendations established by our group are presented as a flow chart taking into account the characteristics of the underlying pathology (malignant or non-malignant), the cell dose and the HLA compatibility criteria, as well as criteria linked to the banks in which units are stored.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S68-S77"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Update for cord blood unit selection in hematopoietic stem cell transplantation (workshop SFGM-TC)].\",\"authors\":\"Valérie Dubois, Lucie Blandin, Marion Duclaut, Alix Duquesne, Lionel Faivre, Romain Ferru-Clement, Jean Roy, Alexandre Walencik, Leonardo Magro, Federico Garnier\",\"doi\":\"10.1016/j.bulcan.2024.01.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Changing practices and the limited use of cord blood units as a source of cells for allogeneic hematopoietic stem cell transplants (HSC) led us to reconsider the recommendations established in 2011 and 2012, and to propose an update incorporating recent bibliographic data. If HLA compatibility was until now established at low resolution for HLA-A and B loci, and at high resolution for HLA-DRB1, the recent papers are converging towards an increase in the level of resolution, making way for a compatibility now defined in high resolution for all the considered loci, and the inclusion of the HLA-C locus, in order to establish a level of HLA compatibility on 8 alleles (HLA-A, B, C and DRB1). The CD34+ dose is a determining factor in hematopoietic reconstitution but it is not correlated with the total nucleated cells content. This is why we recommend taking these two data into account when choosing a cord blood unit. The recommendations established by our group are presented as a flow chart taking into account the characteristics of the underlying pathology (malignant or non-malignant), the cell dose and the HLA compatibility criteria, as well as criteria linked to the banks in which units are stored.</p>\",\"PeriodicalId\":93917,\"journal\":{\"name\":\"Bulletin du cancer\",\"volume\":\" \",\"pages\":\"S68-S77\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin du cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.bulcan.2024.01.009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin du cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.bulcan.2024.01.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/13 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

脐带血作为异基因造血干细胞移植(HSC)的细胞来源,其使用方法不断变化,使用量有限,这促使我们重新考虑2011年和2012年提出的建议,并结合最新的文献数据提出更新建议。迄今为止,HLA相容性是以低分辨率确定HLA-A和B位点,以高分辨率确定HLA-DRB1位点,而最近的论文则趋向于提高分辨率,以高分辨率确定所有考虑位点的相容性,并纳入HLA-C位点,从而确定8个等位基因(HLA-A、B、C和DRB1)的HLA相容性水平。CD34+ 剂量是造血重建的决定性因素,但它与有核细胞的总含量无关。因此,我们建议在选择脐带血单位时将这两个数据考虑在内。我们小组制定的建议以流程图的形式呈现,其中考虑了潜在病理特征(恶性或非恶性)、细胞剂量和 HLA 相容性标准,以及与储存单位所在血库相关的标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Update for cord blood unit selection in hematopoietic stem cell transplantation (workshop SFGM-TC)].

Changing practices and the limited use of cord blood units as a source of cells for allogeneic hematopoietic stem cell transplants (HSC) led us to reconsider the recommendations established in 2011 and 2012, and to propose an update incorporating recent bibliographic data. If HLA compatibility was until now established at low resolution for HLA-A and B loci, and at high resolution for HLA-DRB1, the recent papers are converging towards an increase in the level of resolution, making way for a compatibility now defined in high resolution for all the considered loci, and the inclusion of the HLA-C locus, in order to establish a level of HLA compatibility on 8 alleles (HLA-A, B, C and DRB1). The CD34+ dose is a determining factor in hematopoietic reconstitution but it is not correlated with the total nucleated cells content. This is why we recommend taking these two data into account when choosing a cord blood unit. The recommendations established by our group are presented as a flow chart taking into account the characteristics of the underlying pathology (malignant or non-malignant), the cell dose and the HLA compatibility criteria, as well as criteria linked to the banks in which units are stored.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信